Guus A. M. S. van Dongen

Guus A. M. S. van Dongen

Auto-generated profile, based on publicly available information

Guus A. M. S. van Dongen

Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in The Oncologist
Verified
Journal Article
Closed access
PDF file
GDGuus A.M.S. van Dongen
Guus A.M.S. van Dongen
GVGerard W.M. Visser
Gerard W.M. Visser
MHMarjolijn N. Lub-De Hooge
Marjolijn N. Lub-De Hooge
GVGrietje Knol-de Vries
Grietje Knol-de Vries
LPLars R. Perk
Lars R. Perk
Learning Objectives: After completing this course, the reader will be able to: Discuss the technical advances that have led to recent rapid developments in monoclonal antibody imaging techniques.List the monoclonal antibodies that are currently available for cancer imaging and cancer therapy.Identify potential roles for immuno-PET in cancer staging and treatment selection. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

1 April 2006 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PBPontus K.E. BörJesson
Pontus K.E. BörJesson
YJYvonne W.S. Jauw
Yvonne W.S. Jauw
RBRonald Boellaard
Ronald Boellaard
RBRemco de Bree
Remco de Bree
ECEmile F.I. Comans
Emile F.I. Comans
GDGuus A.M.S. van Dongen
Guus A.M.S. van Dongen
Purpose: Immuno–positron emission tomography (PET), the combination of PET with monoclonal antibodies (mAb), is an attractive option to improve tumor detection and to guide mAb-based therapy. The long-lived positron emitter zirconium-89 (89Zr) has ideal physical characteristics for immuno-PET with intact mAbs but has never been used in a clinical setting. In the present feasibility study, we aimed to evaluate the diagnostic imaging performance of immuno-PET with 89Zr-labeled-chimeric mAb (cmAb) U36 in patients with squamous cell carcinoma of the head and neck (HNSCC), who were at high risk of having neck lymph node metastases.

18 September 2009 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
LPLars R. Perk
Lars R. Perk
MVMaria J. W. D. Vosjan
Maria J. W. D. Vosjan
GVGerard W. M. Visser
Gerard W. M. Visser
MBMarianne Budde
Marianne Budde
PJPaul Jurek
Paul Jurek
GDGuus A. M. S. van Dongen
Guus A. M. S. van Dongen
Purpose Immuno-PET is an emerging imaging tool for the selection of high potential antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89 (89Zr) has attractive characteristics for immuno-PET with intact mAbs. Previously, we have described a multi-step procedure for stable coupling of 89Zr to mAbs via the bifunctional chelate (BFC) tetrafluorophenol-N-succinyldesferal (TFP-N-sucDf). To enable widespread use of 89Zr-immuno-PET, we now introduce the novel BFC p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) and compare its performance in 89Zr-immuno-PET with the reference BFC TFP-N-sucDf. Methods Three mAbs were premodified with Df-Bz-NCS and labeled with 89Zr at different pHs to assess the reaction kinetics and robustness of the radiolabeling. Stability of both 89Zr-Df-Bz-NCS- and 89Zr-N-sucDf-conjugates was evaluated in different buffers and human serum. Comparative biodistribution and PET studies in tumor-bearing mice were undertaken. Results The selected conjugation conditions resulted in a chelate:mAb substitution ratio of about 1.5:1. Under optimal radiolabeling conditions (pH between 6.8–7.2), the radiochemical yield was >85% after 60 min incubation at room temperature, resulting in radioimmunoconjugates with preserved integrity and immunoreactivity. The new radioimmunoconjugate was very stable in serum for up to 7 days at 37°C, with <5% 89Zr release, and was equally stable compared to the reference conjugate when stored in the appropriate buffer at 4°C. In biodistribution and imaging experiments, the novel and the reference radioimmunoconjugates showed high and similar accumulation in tumors in nude mice. Conclusions The novel Df-Bz-NCS BFC allows efficient and easy preparation of optimally performing 89Zr-labeled mAbs, facilitating further exploration of 89Zr-immuno-PET as an imaging tool.

13 January 2004 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
GVG Vandongen
G Vandongen
GVG Visser
G Visser
MVM Vrouenraets
M Vrouenraets

1 August 2003
Verified
Journal Article
Closed access
IVIris Verel
Iris Verel
GVGerard W M Visser
Gerard W M Visser
RBRonald Boellaard
Ronald Boellaard
MWMarijke Stigter-Van Walsum
Marijke Stigter-Van Walsum
GSGordon B Snow
Gordon B Snow
GDGuus A M S Van Dongen
Guus A M S Van Dongen

11 July 2006 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LPLars R. Perk
Lars R. Perk
OVOtto J. Visser
Otto J. Visser
MWM. Stigter-Van Walsum
M. Stigter-Van Walsum
MVMaria J. W. D. Vosjan
Maria J. W. D. Vosjan
GVGerard W. M. Visser
Gerard W. M. Visser
GDGuus A. M. S. van Dongen
Guus A. M. S. van Dongen